AbCellera Biologics Inc (NASDAQ: ABCL) on Tuesday, plunged -7.48% from the previous trading day, before settling in for the closing price of $2.54. Within the past 52 weeks, ABCL’s price has moved between $2.11 and $4.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 376.38% over the last five years. The company achieved an average annual earnings per share of -10.53%. With a float of $223.58 million, this company’s outstanding shares have now reached $295.76 million.
The firm has a total of 596 workers. Let’s measure their productivity. In terms of profitability, gross margin is -188.19%, operating margin of -1091.65%, and the pretax margin is -695.0%.
AbCellera Biologics Inc (ABCL) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of AbCellera Biologics Inc is 24.97%, while institutional ownership is 37.06%.
AbCellera Biologics Inc (ABCL) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -10.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.14% during the next five years compared to -107.74% drop over the previous five years of trading.
AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators
AbCellera Biologics Inc (ABCL) is currently performing well based on its current performance indicators. A quick ratio of 9.81 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.55, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.65 in one year’s time.
Technical Analysis of AbCellera Biologics Inc (ABCL)
Analysing the last 5-days average volume posted by the [AbCellera Biologics Inc, ABCL], we can find that recorded value of 3.56 million was lower than the volume posted last year of 4.25 million. As of the previous 9 days, the stock’s Stochastic %D was 74.23%. Additionally, its Average True Range was 0.19.
During the past 100 days, AbCellera Biologics Inc’s (ABCL) raw stochastic average was set at 15.29%, which indicates a significant decrease from 26.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.80% in the past 14 days, which was higher than the 70.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.95, while its 200-day Moving Average is $2.88. Now, the first resistance to watch is $2.47. This is followed by the second major resistance level at $2.58. The third major resistance level sits at $2.65. If the price goes on to break the first support level at $2.29, it is likely to go to the next support level at $2.22. Should the price break the second support level, the third support level stands at $2.11.
AbCellera Biologics Inc (NASDAQ: ABCL) Key Stats
Market capitalization of the company is 700.27 million based on 297,988K outstanding shares. Right now, sales total 28,830 K and income totals -162,860 K. The company made 5,050 K in profit during its latest quarter, and -34,210 K in sales during its previous quarter.
